Skip to main content
. 2018 Dec 11;10(4):268. doi: 10.3390/pharmaceutics10040268

Figure 6.

Figure 6

Examples of DNA nanostructures developed for the delivery of therapeutic oligonucleotides. (a) Release of siRNA encapsulated in DNA prisms monitored by a FRET reporter system, adapted with permission from [191]. (b) Schematic illustration of “dual lock-and-key” DNA-based nanovehicle for a cell-specific siRNA delivery, adapted with permission from [192]. (c) Immunostimulatory-SNAs exhibited high potency and high IgG2a serum titers, adapted with permission from [195]. (d) Process of rolling circle transcription (RCT) for the assembling of RNAi microsponges, where a linear ssDNA including antisense and sense of anti-luciferase siRNA is hybridized with DNA strands holding the promoter T7 promoter sequence, adapted with permission from [196]. (e) DNA origami-based device for synergistic breast cancer treatment using RNAi therapy (p53 gene) and chemotherapy (DOX), adapted with permission from [203].